Charles Schwab Investment Management Inc. Increases Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Charles Schwab Investment Management Inc. increased its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 9.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 622,297 shares of the company's stock after purchasing an additional 53,721 shares during the quarter. Charles Schwab Investment Management Inc. owned 1.28% of Nurix Therapeutics worth $6,422,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its holdings in Nurix Therapeutics by 351.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,611 shares of the company's stock worth $58,000 after purchasing an additional 4,367 shares during the period. International Assets Investment Management LLC acquired a new position in shares of Nurix Therapeutics during the fourth quarter valued at approximately $1,175,000. Principal Financial Group Inc. raised its holdings in shares of Nurix Therapeutics by 14.8% during the third quarter. Principal Financial Group Inc. now owns 15,531 shares of the company's stock valued at $122,000 after acquiring an additional 2,002 shares during the last quarter. Exchange Traded Concepts LLC raised its holdings in shares of Nurix Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 15,823 shares of the company's stock valued at $163,000 after acquiring an additional 4,012 shares during the last quarter. Finally, New York State Common Retirement Fund raised its holdings in shares of Nurix Therapeutics by 59.5% during the fourth quarter. New York State Common Retirement Fund now owns 16,156 shares of the company's stock valued at $167,000 after acquiring an additional 6,025 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on NRIX shares. HC Wainwright reduced their target price on Nurix Therapeutics from $35.00 to $19.00 and set a "buy" rating for the company in a report on Tuesday, February 20th. Stephens started coverage on Nurix Therapeutics in a report on Tuesday, May 14th. They set an "overweight" rating and a $20.00 target price for the company. Stifel Nicolaus reissued a "buy" rating and set a $27.00 target price on shares of Nurix Therapeutics in a report on Wednesday, May 15th. Needham & Company LLC reissued a "buy" rating and set a $31.00 target price on shares of Nurix Therapeutics in a report on Tuesday, May 14th. Finally, Wells Fargo & Company dropped their price target on Nurix Therapeutics from $23.00 to $20.00 and set an "overweight" rating for the company in a research report on Friday, February 16th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $21.88.

Insider Buying and Selling

In related news, CFO Houte Hans Van sold 3,499 shares of the stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $12.83, for a total value of $44,892.17. Following the completion of the transaction, the chief financial officer now directly owns 68,333 shares in the company, valued at $876,712.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders sold 6,893 shares of company stock worth $85,756. Company insiders own 7.20% of the company's stock.

Nurix Therapeutics Stock Performance

Shares of NRIX stock traded up $0.30 during trading hours on Monday, reaching $16.05. The company had a trading volume of 599,519 shares, compared to its average volume of 946,196. The stock has a fifty day moving average of $14.52 and a 200-day moving average of $11.35. The company has a market capitalization of $788.87 million, a price-to-earnings ratio of -6.12 and a beta of 2.10. Nurix Therapeutics, Inc. has a 12-month low of $4.22 and a 12-month high of $18.12.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings data on Wednesday, April 10th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.04. The company had revenue of $16.59 million during the quarter, compared to analyst estimates of $14.58 million. Nurix Therapeutics had a negative return on equity of 67.08% and a negative net margin of 178.93%. On average, analysts forecast that Nurix Therapeutics, Inc. will post -3.09 EPS for the current year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.